Meditation for Emotional Numbing in Post-Traumatic Stress Disorder
Meditation Training for Emotional Numbing in Post-traumatic Stress Disorder
1 other identifier
interventional
20
1 country
1
Brief Summary
For individuals suffering from posttraumatic stress disorder (PTSD), the emotional numbing and isolation that are a core aspect of their suffering and consistently impedes remediation often remains after first-line treatments are administered. Few interventions have proven successful for enhancing the empathy and social connectedness that will ultimately allow patients to flourish, and the search for target therapies is made more difficult by the fact that very little is known about the underlying physiology of emotional numbing and social isolation. The proposed study is designed to (1) investigate the hormonal, neural and immunological biomarkers related to emotional numbing, and (2) test whether cognitively-based compassion training (CBCT), an intervention designed and proven to enhance empathy, will reduce emotional numbing and increase empathy and social connectedness in veterans. To this end, thirty medically healthy males diagnosed with PTSD who continue to report emotional numbing symptoms after prolonged exposure therapy will receive 8 weeks of training in CBCT. Prior to, and again after the training, the investigators will assess patients' levels of oxytocin, inflammation, and self-reported emotional numbing and social connectedness. The investigators will also assess their neural response during a video task that assesses their ability to accurately read others' emotions. The investigators hypothesize that oxytocin, neural activity, and inflammation will predict social numbing, isolation, and empathy, and also that CBCT will positively impact the social outcomes that will pave the way toward health and well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started May 2014
Typical duration for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
June 11, 2014
CompletedFirst Posted
Study publicly available on registry
June 16, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedAugust 2, 2016
July 1, 2016
2 years
June 11, 2014
July 30, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Social connectedness
Self-report questionnaire assessment of social connectedness
up to 3 months
Empathic Accuracy
objective performance assessing accuracy of reading others' emotions
up to 3 months
Social Interactions
objective measures of time spent with others as measured by an audio sampling device
up to 3 months
Secondary Outcomes (1)
messenger ribonucleic acid (mRNA)
up to 3 months
Study Arms (1)
Compassion Training
EXPERIMENTAL8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
Interventions
Eligibility Criteria
You may qualify if:
- previously met criteria for PTSD
- completed front-line treatment such as prolonged exposure therapy
- continue to report emotional numbing symptoms as a chief complaint
You may not qualify if:
- Self-reported psychotic symptoms, current major depression, or suicidal ideation
- Self-reported active alcohol or drug abuse within the past six months
- Self-reported depression serious enough to require hospitalization, or that resulted in a suicide attempt, within the last year.
- Self-reported auto-immune disease such as lupus, crohn's disease, irritable bowel syndrome, or rheumatoid arthritis.
- Self-reported use of psychotropic medication, including antidepressants, mood stabilizers, antipsychotics or chronic benzodiazepine therapy that has changed in the past 6 weeks.
- Self-reported use of any medication that might strongly affect your stress or immune systems, including non-steroidal anti-inflammatory agents, COX-2 inhibitors, corticosteroids, beta-blockers or statins.
- Claustrophobia
- Ferromagnetic implants contraindicated by functional MRI (fMRI) safety regulations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emory Universitylead
- Brain & Behavior Research Foundationcollaborator
- Mind and Life Institute, Hadley, Massachusettscollaborator
Study Sites (1)
Emory University
Atlanta, Georgia, 30322, United States
Related Publications (4)
Mascaro JS, Rilling JK, Tenzin Negi L, Raison CL. Compassion meditation enhances empathic accuracy and related neural activity. Soc Cogn Affect Neurosci. 2013 Jan;8(1):48-55. doi: 10.1093/scan/nss095. Epub 2012 Sep 5.
PMID: 22956676BACKGROUNDDesbordes G, Negi LT, Pace TW, Wallace BA, Raison CL, Schwartz EL. Effects of mindful-attention and compassion meditation training on amygdala response to emotional stimuli in an ordinary, non-meditative state. Front Hum Neurosci. 2012 Nov 1;6:292. doi: 10.3389/fnhum.2012.00292. eCollection 2012.
PMID: 23125828BACKGROUNDPace TW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, Issa MJ, Raison CL. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009 Jan;34(1):87-98. doi: 10.1016/j.psyneuen.2008.08.011. Epub 2008 Oct 4.
PMID: 18835662BACKGROUNDPace TW, Negi LT, Sivilli TI, Issa MJ, Cole SP, Adame DD, Raison CL. Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinology. 2010 Feb;35(2):310-5. doi: 10.1016/j.psyneuen.2009.06.008. Epub 2009 Jul 16.
PMID: 19615827BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer S Mascaro, PhD
Emory University
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Instructor
Study Record Dates
First Submitted
June 11, 2014
First Posted
June 16, 2014
Study Start
May 1, 2014
Primary Completion
May 1, 2016
Study Completion
May 1, 2016
Last Updated
August 2, 2016
Record last verified: 2016-07